Form 4: Pfizer CFO David Denton Reports Stock Transaction
SEC Form 4 Filing
Pfizer's Chief Financial Officer, David M. Denton, reported a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- On May 31, 2024, David M. Denton, the Chief Financial Officer and EVP of Pfizer Inc., reported a transaction.
- The transaction involved the withholding of 12,107 common stock shares at a price of $28.66 to satisfy tax obligations upon the vesting of restricted stock units.
- Following the transaction, Denton directly owns 37,919 shares of Pfizer common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of a routine transaction related to tax obligations on vested stock units. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their holdings in the company's stock. This filing indicates the CFO's stock transactions related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/31/2024 | Date of the reported transaction involving the withholding of shares. |
| 06/03/2024 | Date of signature on the report by Susan E. Grant, by power of attorney, for David M. Denton. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.